Medpace
MEDP
$605.82
+14.71%
Medpace is a late-stage contract research organization (CRO) that provides full-service drug development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms, along with ancillary services like bioanalytical laboratory and imaging capabilities. It occupies a distinct niche as a specialized CRO focused on mid-sized biotech clients, differentiating itself from larger competitors through its therapeutic expertise and full-service model. The current investor narrative centers on Medpace's strong revenue growth trajectory, driven by robust demand for clinical trials, but is tempered by recent analyst downgrades and a sharp stock price correction in early 2026 following a significant earnings-related drop.…
MEDP
Medpace
$605.82
Related headlines
Investment Opinion: Should I buy MEDP Today?
Rating: Hold. Medpace is a high-quality growth company with accelerating revenue and strong margins, but its premium valuation and cautious analyst consensus suggest limited upside from current levels. The average analyst target of $472.33 implies 12.2% downside, and the consensus hold rating (2.92/5) reflects balanced risk/reward. Supporting Evidence: Revenue growth accelerated to 26.5% YoY, net margin is 17.5%, FCF TTM is $737.8M, and the company has zero debt. However, the trailing P/E of 35.9x is above the industry average, and the stock trades near the high end of its historical P/E range. The implied downside to the average target and recent downgrades temper enthusiasm. Risks & Conditions: The Hold rating would upgrade to Buy if the stock pulls back to the analyst low target of $329 (39% downside) or if revenue growth sustains above 25% with margin expansion. It would downgrade to Sell if growth decelerates below 15% or gross margins fall below 25%. Overall, Medpace is fairly valued relative to its growth but overvalued relative to peers, making it a hold for existing investors and a wait for new buyers.
Sign up to view all
MEDP 12-Month Price Forecast
Medpace's strong operational metrics are offset by a premium valuation and cautious analyst sentiment. The base case of moderate growth and stable margins is most likely, with a 55% probability. The stock offers limited upside from current levels, but the downside is also contained by the company's debt-free balance sheet and strong cash flows. A neutral stance is appropriate until either the valuation becomes more attractive or growth accelerates further. Upgrading to bullish would require a pullback to the $470 level or a clear catalyst like a major contract win.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Medpace's 12-month outlook, with a consensus price target around $472.33 and implied upside of -22.0% versus the current price.
Average Target
$472.33
0 analysts
Implied Upside
-22.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$329 - $586
Analyst target range
Medpace is covered by 12 analysts, with a consensus recommendation of 'hold' (mean rating 2.92 on a 1-5 scale where 1 is strong buy). The average target price is $472.33, implying a -12.2% downside from the current price of $537.73. The distribution shows 4 buys, 5 holds, and 3 sells, indicating a cautious stance. The target range spans from a low of $329.00 to a high of $586.00. The high target of $586 assumes continued strong growth and margin expansion, while the low target of $329 reflects risks such as client concentration or industry headwinds. Recent ratings changes show a bearish tilt: Baird downgraded from Outperform to Neutral on July 8, and Jefferies downgraded from Buy to Hold on July 7. However, Mizuho reiterated Outperform on July 13. The wide spread between low and high targets ($257) signals high uncertainty about Medpace's future performance.
Bulls vs Bears: MEDP Investment Factors
Medpace presents a compelling growth story with accelerating revenue, high profitability, and a fortress balance sheet. However, the stock trades at a premium valuation that leaves limited upside, and analyst sentiment is cautious with a consensus hold and 12% downside to the average target. The single most important tension is whether the company's strong operational momentum can justify its premium multiple, or if valuation compression will erode returns. Currently, the bear case has slightly stronger evidence due to the unfavorable risk/reward at current levels, but a positive earnings surprise or upward guidance revision could quickly shift the balance.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 26.5% YoY to $706.6M, accelerating from 13.2% in Q2 2025 and 18.8% in Q3 2025, indicating strong demand for clinical trial services.
- High Profitability and Margins: Net margin of 17.5% and operating margin of 20.0% in Q1 2026 demonstrate efficient cost management and pricing power, with ROE at an exceptional 98.3%.
- Strong Free Cash Flow Generation: TTM free cash flow of $737.8M and Q1 2026 FCF of $145.0M provide ample liquidity for reinvestment and share buybacks, supporting shareholder returns.
- Debt-Free Balance Sheet: With $652.7M in cash and no debt (debt-to-equity of 0.55 including operating leases), Medpace has minimal financial risk and flexibility to weather downturns.
Bearish
- Analyst Consensus Hold with Downside: 12 analysts rate MEDP a 'hold' with an average target of $472.33, implying 12.2% downside from the current price of $537.73. Recent downgrades from Baird and Jefferies add caution.
- Premium Valuation vs. Peers: Trailing P/E of 35.9x and PS ratio of 6.4x are above industry medians (PS ~3-4x), suggesting the market already prices in high growth expectations, leaving little room for error.
- Sharp Price Correction and Volatility: The stock fell 36.6% from its 52-week high of $628.92 to a low of $306.70, and beta of 1.15 indicates 15% higher volatility than the market, amplifying downside risk.
- Gross Margin Compression: Gross margin declined from 31.9% in Q1 2025 to 27.8% in Q1 2026, potentially signaling pricing pressure or rising costs that could squeeze profitability if not offset by scale.
MEDP Technical Analysis
Medpace's 1-year price change of +68.5% reflects a strong uptrend, but the stock has experienced significant volatility. The current price of $537.73 sits at 68.5% of its 52-week range ($306.70 low to $628.92 high), indicating it has recovered from its lows but remains well below the highs. This positioning suggests the stock is in a recovery phase after a sharp decline, but not yet back to peak momentum. The 1-month price change of +17.6% shows strong short-term recovery, while the 3-month change of +3.3% is modest, and the 6-month change of -12.0% highlights the earlier selloff. The divergence between the strong 1-month rally and the negative 6-month trend suggests a potential trend reversal or mean reversion, but the stock is still below its 52-week high. The 52-week low of $306.70 provides key support, while the 52-week high of $628.92 is a major resistance level. A breakout above $628.92 would signal a resumption of the long-term uptrend, while a breakdown below $306.70 would indicate further downside. Beta of 1.15 implies the stock is 15% more volatile than the market, meaning it amplifies market moves, which is important for risk management.
Beta
—
—
Max Drawdown
-36.6%
Largest decline past year
52-Week Range
$373-$678
Price range past year
Annual Return
+38.5%
Cumulative gain past year
| Period | MEDP Return | S&P 500 |
|---|---|---|
| 1m | +28.0% | +0.6% |
| 3m | +47.6% | +3.4% |
| 6m | +3.0% | +7.1% |
| 1y | +38.5% | +16.4% |
| ytd | +6.1% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MEDP Fundamental Analysis
Medpace's revenue trajectory is strongly growing, with Q1 2026 revenue of $706.6 million, up 26.5% year-over-year from $558.6 million in Q1 2025. This marks an acceleration from the 13.2% YoY growth in Q2 2025 and 18.8% in Q3 2025, indicating the company is gaining momentum. Revenue segments show Metabolic ($237.6M) and Oncology ($201.2M) as the largest drivers, together accounting for 62% of total revenue. The company is highly profitable, with Q1 2026 net income of $123.9 million and a net margin of 17.5%. Gross margin was 27.8% in Q1 2026, slightly down from 31.9% in Q1 2025, but operating margin improved to 20.0% from 20.3% a year ago, showing stable profitability. Medpace has a strong balance sheet with $652.7 million in cash and no debt, as debt-to-equity is 0.55 (including operating leases). Free cash flow TTM is $737.8 million, and the company generated $144.97 million in FCF in Q1 2026 alone. ROE is an exceptional 98.3%, reflecting high returns on equity, though this is partly due to share repurchases reducing equity. The current ratio of 0.74 indicates some liquidity risk, but the strong cash position mitigates this.
Quarterly Revenue
$706604000.0B
2026-03
Revenue YoY Growth
+26.5%
YoY Comparison
Gross Margin
27.8%
Latest Quarter
Free Cash Flow
$737819000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MEDP Overvalued?
Since Medpace has positive net income, we use the P/E ratio as the primary valuation metric. The trailing P/E is 35.9x, while the forward P/E is 28.7x, implying the market expects earnings growth to reduce the multiple. The gap between trailing and forward P/E suggests investors anticipate continued strong earnings growth. Compared to the industry (Medical - Diagnostics & Research), Medpace trades at a premium. The industry average P/E is not provided, but the PS ratio of 6.4x is above the sector median of around 3-4x for CROs, indicating a premium valuation. This premium may be justified by Medpace's superior revenue growth (26.5% YoY) and high profitability (net margin 17.5%) versus peers. Historically, Medpace's trailing P/E of 35.9x is near the lower end of its 5-year range (which has been as high as 40x+ in 2021 and as low as 20x in 2022). The current P/E is below the 2021 peak but above the 2022 trough, suggesting the stock is reasonably valued relative to its history, not excessively overvalued.
PE
35.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 18x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Medpace's gross margin compression from 31.9% to 27.8% YoY raises concerns about pricing pressure or cost inflation. Although operating margin improved to 20.0%, any further margin erosion could pressure earnings. The current ratio of 0.74 indicates potential liquidity risk, though the $652.7M cash balance and no debt mitigate this. Revenue concentration in Metabolic (34%) and Oncology (28%) segments exposes the company to sector-specific downturns. Market & Competitive Risks: The stock's beta of 1.15 means it amplifies market moves, and its premium valuation (P/E 35.9x vs. industry ~20-25x) makes it vulnerable to multiple compression if growth slows. Recent analyst downgrades (Baird, Jefferies) reflect growing skepticism. The CRO industry faces competitive pressure from larger players like IQVIA and Labcorp, which could win share. Worst-Case Scenario: A combination of revenue growth deceleration below 10%, further margin contraction, and a broad market selloff could drive the stock to its 52-week low of $306.70, representing a 43% decline from the current price. This scenario would likely involve client cancellations or a biotech funding winter, leading to earnings misses and multiple compression to historical trough levels.
FAQ
The key risks are: 1) Valuation risk: At 35.9x trailing P/E, the stock is vulnerable to multiple compression if growth slows. 2) Margin risk: Gross margin declined from 31.9% to 27.8% YoY, which could pressure earnings if not reversed. 3) Competitive risk: Larger CROs like IQVIA could win market share, especially if Medpace's mid-cap clients face funding issues. 4) Macro risk: Beta of 1.15 means the stock amplifies market downturns, and a biotech funding winter could reduce demand. The most severe risk is a 43% decline to the 52-week low of $306.70 if growth decelerates sharply.
The 12-month outlook is mixed. The bull case (20% probability) sees the stock reaching $586-$629, driven by sustained 25%+ growth and margin expansion. The base case (55% probability) targets $472-$538, with growth moderating to 18-20% and the stock trading near the analyst average. The bear case (25% probability) sees a decline to $329-$416 if growth falls below 15% and margins compress. The most likely scenario is the base case, with the stock hovering around current levels or slightly lower. Key assumptions include stable gross margins and no major analyst downgrades.
MEDP appears overvalued relative to its industry peers but fairly valued relative to its own growth rate. The trailing P/E of 35.9x is above the CRO industry median of around 25x, and the PS ratio of 6.4x exceeds the sector median of 3-4x. However, the PEG ratio of 1.82x suggests the stock is reasonably priced given its earnings growth. Historically, the current P/E is near the middle of its 5-year range (20x-40x+), indicating it is not at extreme levels. The market is pricing in continued strong growth, and any disappointment could lead to multiple compression. Overall, MEDP is overvalued on a peer comparison but fairly valued on a growth-adjusted basis.
At $537.73, MEDP offers a mixed risk/reward. The company has strong fundamentals: 26.5% revenue growth, 17.5% net margin, and zero debt. However, the stock trades at a trailing P/E of 35.9x, above the industry average, and analysts see 12.2% downside to their average target of $472.33. The biggest risk is valuation compression if growth slows. For long-term investors willing to hold through volatility, MEDP could be a good buy on pullbacks near $470 or lower. For short-term traders, the stock's beta of 1.15 offers opportunities but also risks. Overall, it's a hold for existing investors and a cautious buy for new investors at a better entry point.
MEDP is better suited for long-term investment due to its strong growth trajectory, high profitability, and debt-free balance sheet. The stock's beta of 1.15 and recent volatility (36.6% max drawdown) make it risky for short-term trading. The company pays no dividend, so returns come from capital appreciation. With a PEG ratio of 1.82x, the stock offers reasonable value for long-term holders who can tolerate interim volatility. A minimum holding period of 3-5 years is recommended to allow the growth story to play out and to ride out market cycles. Short-term traders may find opportunities around earnings events, but the risk of sharp moves is high.